Compliance updated on Jun 19, 2026 Screened by AAOIFI-Certified Shariah Advisor & Auditor

Financial data updated nightly

Fulcrum Therapeutics Inc

FULC ✓ COMPLIANT ☆ Track — members

Nasdaq · Healthcare · Biotechnology & Medical Research ·

USA Micro Cap Analyst: HOLD

Last Close

$3.74

▲ +0.81%

Market Cap $285.35M · Vol 334.82K

Key Metrics

P/E Ratio

N/A

FWD: N/A

Market Cap

$285.35M

Micro Cap

Div Yield

N/A

EPS Growth

+35.96%

YoY

RSI (14)

50.51

Momentum

Beta

2.57

vs Market

52W High

$15.50

75.87% below

52W Low

$2.91

28.52% above

Volume

334.82K

Avg 514.20K

P/B

2.16

Price-to-book

ROE

-25.30%

Return on equity

Free Float

96.12%

Public shares

Shariah Compliance8 STANDARDS

✓ Yes, Fulcrum Therapeutics Inc (FULC) stock is Shariah compliant

AAOIFI—
Dow Jones Islamic (DJIM)—
FTSE Shariah—
MSCI Islamic—
S&P Shariah—
Al Rajhi—
Alinma—
Albilad—

Unlock the full Shariah report

See the verdict under each standard, the exact screening ratios, purification and zakat per share. AAOIFI-certified methodology trusted by global Islamic funds.

Which standards does FULC pass?

The full report shows the verdict under each of the 8 major Shariah standards, with the business-activity and financial-ratio screens behind every one.

Do I need to purify my investment?

Members see the purification amount per share, updated every financial period under the AAOIFI methodology.

Can I calculate zakat for my shares?

Members get zakat per share and a built-in calculator for their exact holding.

Historical Returns

-3.86%

+4.18%

-47.40%

-64.82%

YTD

-66.93%

-43.33%

-11.58%

-83.69%

Financials & Valuation

TTM · Annual

Total Revenue	$0.00
Net Income	$-74,880,000.00
Revenue Growth (YoY)	N/A
Gross Margin	N/A
Operating Margin	N/A
Net Profit Margin	N/A
ROE	-25.30%
ROA · ROIC	-23.89% · N/A

P/E Ratio	N/A
Forward P/E (FY1)	N/A
PEG Ratio	N/A
P/S	N/A
P/B	2.16
P/FCF	N/A
EPS Growth	+35.96%
Outstanding Shares	76.30M

Technical Indicators

50-Day SMA	$3.66
200-Day SMA	$7.68
RSI (14)	50.51
Beta	2.57
52-Week High	$15.50
52-Week Low	$2.91

Volume Today	334.82K
Avg Daily Volume (30D)	514.20K
Relative Volume	0.65x
Volatility (10D)	33.32
Volatility (30D)	34.37
Free Float	96.12%

Analyst Consensus

HOLD

Current Price $3.74

Mean Target $6.83

52W Low$2.91 52W High$15.50

Current

Target

$2.91 $15.50

Current Analyst target

+82.71% upside potential · 7 analysts

Identifiers

ExchangeNasdaq

FIGIBBG00DDY1RM7

ISINUS3596161097

CountryUnited States of America

Sub-IndustryBiotechnology & Medical Research (NEC)

Earnings DateOct 27, 2026

TypeStocks

Instrument TypeORD Ordinary Share

Similar Halal Stocks

LONN.S Lonza Group AG -1.78% RVMD Revolution Medicines Inc +0.85% ONC BeOne Medicines AG -2.40% 068270.KS Celltrion Inc -0.50% ABVX Abivax SA -2.05%

Company Profile

Fulcrum Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing small molecules to improve the lives of patients with genetically defined rare diseases in areas of high unmet medical need. The Company's lead clinical program is pociredir, a small molecule designed to increase expression of fetal hemoglobin for the treatment of sickle cell disease (SCD). It uses technology to identify drug targets that can modulate gene expression to treat the known root cause of gene mis-expression. In addition to its product candidates, the Company has developed a discovery approach that it employs to systematically identify and validate cellular drug targets that can potentially modulate gene expression to treat known root causes of genetically defined rare diseases. The Company continues to advance its program for the potential treatment of inherited aplastic anemias, such as Diamond-Blackfan anemia (DBA), Shwachman-Diamond syndrome, and Fanconi anemia.